Pilar Martinez-Martinez

DGAT1 overexpression in muscle by in vivo DNA electroporation increases intramyocellular lipid content.

Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.

A human-specific TNF-responsive promoter for Goodpasture antigen-binding protein.

Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis.

Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange.

Generation of polyclonal antibodies directed against G protein-coupled receptors using electroporation-aided DNA immunization.

Treatment of myasthenia gravis by preventing acetylcholine receptor modulation.

Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil.

Goodpasture antigen-binding protein is a soluble exportable protein that interacts with type IV collagen. Identification of novel membrane-bound isoforms.

Silencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane folding.

Delivery of peptide and protein drugs over the blood-brain barrier.

The expression of the Goodpasture antigen-binding protein (ceramide transporter) in adult rat brain.

The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates.

The ceramide transporter and the Goodpasture antigen binding protein: one protein--one function?

The auto-antigen repertoire in myasthenia gravis.

Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.

Low Current-driven Micro-electroporation Allows Efficient In Vivo Delivery of Nonviral DNA into the Adult Mouse Brain.

Clinical staging of HIV-related illness in Mozambique: performance of nonphysician clinicians based on direct observation of clinical care and implications for health worker training.

In vivo electroporation of the central nervous system: a non-viral approach for targeted gene delivery.

Task shifting in Mozambique: cross-sectional evaluation of non-physician clinicians' performance in HIV/AIDS care.

Reduced thymic expression of ErbB receptors without auto-antibodies against synaptic ErbB in myasthenia gravis.

Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.

Paradoxical increase in TAG and DAG content parallel the insulin sensitizing effect of unilateral DGAT1 overexpression in rat skeletal muscle.

Neuropathy-induced spinal GAP-43 expression is not a main player in the onset of mechanical pain hypersensitivity.

Unchanged expression of the ceramide transfer protein in the acute 6-OHDA neurodegenerative model.

Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.

Goodpasture antigen-binding protein/ceramide transporter binds to human serum amyloid P-component and is present in brain amyloid plaques.

MuSK myasthenia gravis and Lambert-Eaton myasthenic syndrome in the same patient.

Ceramide function in the brain: when a slight tilt is enough.

The effects of fetal and perinatal asphyxia on neuronal cytokine levels and ceramide metabolism in adulthood.

Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?

Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis.

Fetal asphyctic preconditioning modulates the acute cytokine response thereby protecting against perinatal asphyxia in neonatal rats.

Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4.

Fetal asphyxia induces acute and persisting changes in the ceramide metabolism in rat brain.

Autoantigen induced clonal expansion in immortalized B cells from the peripheral blood of multiple sclerosis patients.

Proteomic analysis of rat tibialis anterior muscles at different stages of experimental autoimmune myasthenia gravis.

Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders.

Complement activation by ceramide transporter proteins.

Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor.

Delivery of DNA into the central nervous system via electroporation.

Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients.

Glycine receptor antibodies in PERM: a new channelopathy.

Guidelines for pre-clinical assessment of the acetylcholine receptor-specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs.

Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors - Recommendations for methods and experimental designs.

Absence of N-Methyl-D-Aspartate Receptor IgG Autoantibodies in Schizophrenia: The Importance of Cross-Validation Studies.

Detection of Peptide-based nanoparticles in blood plasma by ELISA.